Floatz logo

Targeted Aml1-Eto Neoantigen Cytotoxic T Cells

Neoantigen

BGI, ChinaCell therapyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
89/ 100

Competitive context

3 Active assets in the Neoantigen cohort.

Asset / SponsorPhaseRating
Decitabine
BGI, China
Early Phase 1C
Cyclophosphamide
BGI, China
Early Phase 1C
Mitoxantrone
BGI, China
Early Phase 1C

Same molecule, other indications

Targeted Aml1-Eto Neoantigen Cytotoxic T Cells is also rated in:

acute myeloid leukemia with t(8;21)(q22;q22) translocationDormant
C
Indicative ·
39 / 100
View asset →
acute myeloid leukemiaDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →